Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bridion sugammadex regulatory update

FDA canceled the July 18 meeting of the Anesthetic and Analgesic Drug Products Advisory Committee to discuss a resubmitted NDA from Merck for sugammadex

Read the full 241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE